These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24811400)

  • 1. Dornase Alfa for Non-Cystic Fibrosis Pediatric Pulmonary Atelectasis.
    Thornby KA; Johnson A; Axtell S
    Ann Pharmacother; 2014 Aug; 48(8):1040-1049. PubMed ID: 24811400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of dornase alfa in the treatment of cystic fibrosis.
    Cramer GW; Bosso JA
    Ann Pharmacother; 1996 Jun; 30(6):656-61. PubMed ID: 8792953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Inhaled Dornase Alfa Administration in Non-Cystic Fibrosis Patients at a Tertiary Academic Medical Center.
    Torbic H; Hacobian G
    J Pharm Pract; 2016 Oct; 29(5):480-3. PubMed ID: 25667210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease.
    Cimmino M; Nardone M; Cavaliere M; Plantulli A; Sepe A; Esposito V; Mazzarella G; Raia V
    Arch Otolaryngol Head Neck Surg; 2005 Dec; 131(12):1097-101. PubMed ID: 16365224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dornase alfa (Pulmozyme).
    Wagener JS; Kupfer O
    Curr Opin Pulm Med; 2012 Nov; 18(6):609-14. PubMed ID: 22990660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic rhinosinusitis with dornase alfa in patients with cystic fibrosis: a systematic review.
    Shah GB; De Keyzer L; Russell JA; Halderman A
    Int Forum Allergy Rhinol; 2018 Jun; 8(6):729-736. PubMed ID: 29323796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change.
    VanDevanter DR; Craib ML; Pasta DJ; Millar SJ; Morgan WJ; Konstan MW;
    Pediatr Pulmonol; 2018 Jan; 53(1):43-49. PubMed ID: 29064184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dornase alfa: a new option in the management of cystic fibrosis.
    Witt DM; Anderson L
    Pharmacotherapy; 1996; 16(1):40-8. PubMed ID: 8700791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of dornase alfa in the paediatric intensive care unit: current literature and a national cross-sectional survey.
    den Hollander B; Linssen RSN; Cortjens B; van Etten-Jamaludin FS; van Woensel JBM; Bem RA;
    Eur J Hosp Pharm; 2022 May; 29(3):123-128. PubMed ID: 33122405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of inhaled mannitol/dornase alfa combination and daily dornase alfa alone in children with cystic fibrosis.
    Ademhan Tural D; Yalçın E; Emiralioglu N; Ozsezen B; Sunman B; Nayir Buyuksahin H; Guzelkas I; Dogru D; Ozcelik U; Kiper N
    Pediatr Pulmonol; 2022 Jan; 57(1):142-151. PubMed ID: 34687284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dornase alfa.
    Shah PL; Hodson ME
    BioDrugs; 1997 Dec; 8(6):439-45. PubMed ID: 18031106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.
    Fitzgerald DA; Hilton J; Jepson B; Smith L
    Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human deoxyribonuclease shortens ventilation time in young, mechanically ventilated children.
    Riethmueller J; Borth-Bruhns T; Kumpf M; Vonthein R; Wiskirchen J; Stern M; Hofbeck M; Baden W
    Pediatr Pulmonol; 2006 Jan; 41(1):61-6. PubMed ID: 16265663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and in vitro effect of dornase alfa in mechanically ventilated pediatric non-cystic fibrosis patients with atelectases.
    Riethmueller J; Kumpf M; Borth-Bruhns T; Brehm W; Wiskirchen J; Sieverding L; Ankele C; Hofbeck M; Baden W
    Cell Physiol Biochem; 2009; 23(1-3):205-10. PubMed ID: 19255515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasally inhaled dornase alfa in the postoperative management of chronic sinusitis due to cystic fibrosis.
    Raynor EM; Butler A; Guill M; Bent JP
    Arch Otolaryngol Head Neck Surg; 2000 May; 126(5):581-3. PubMed ID: 10807324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis.
    McKenzie SG; Chowdhury S; Strandvik B; Hodson ME;
    Pediatr Pulmonol; 2007 Oct; 42(10):928-37. PubMed ID: 17726701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bronchoscopic instillation of DNase to manage refractory lobar atelectasis in a lung cancer patient.
    Assallum H; Song TY; DeLorenzo L; Harris K
    Ann Transl Med; 2019 Aug; 7(15):363. PubMed ID: 31516909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dornase alpha compared to hypertonic saline for lung atelectasis in critically ill patients.
    Youness HA; Mathews K; Elya MK; Kinasewitz GT; Keddissi JI
    J Aerosol Med Pulm Drug Deliv; 2012 Dec; 25(6):342-8. PubMed ID: 22413805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
    Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
    J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.